WallStSmart

Eli Lilly and Company (LLY)vsOneMedNet Corp. (ONMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 5481615% more annual revenue ($72.25B vs $1.32M). LLY leads profitability with a 35.0% profit margin vs -254.3%. LLY earns a higher WallStSmart Score of 78/100 (B+).

LLY

Strong Buy

78

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 5.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.06

ONMD

Avoid

13

out of 100

Grade: F

Growth: 4.0Profit: 2.5Value: 6.7Quality: 3.8
Piotroski: 5/9Altman Z: -73.01
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LLY.

ONMDUndervalued (+75.0%)

Margin of Safety

+75.0%

Fair Value

$2.34

Current Price

$0.77

$1.57 discount

UndervaluedFair: $2.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LLY6 strengths · Avg: 10.0/10
Market CapQuality
$948.95B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

Profit MarginProfitability
35.0%10/10

Keeps 35 of every $100 in revenue as profit

Operating MarginProfitability
49.4%10/10

Strong operational efficiency at 49.4%

Revenue GrowthGrowth
55.5%10/10

Revenue surging 55.5% year-over-year

EPS GrowthGrowth
169.9%10/10

Earnings expanding 169.9% YoY

ONMD0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

LLY3 concerns · Avg: 3.0/10
P/E RatioValuation
37.7x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
1.393/10

Elevated debt levels

Price/BookValuation
32.4x2/10

Trading at 32.4x book value

ONMD4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$36.83M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Revenue GrowthGrowth
-29.9%2/10

Revenue declined 29.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.

Bull Case : ONMD

ONMD has a balanced fundamental profile.

Bear Case : LLY

The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.

Bear Case : ONMD

The primary concerns for ONMD are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

LLY profiles as a growth stock while ONMD is a turnaround play — different risk/reward profiles.

ONMD carries more volatility with a beta of 1.12 — expect wider price swings.

LLY is growing revenue faster at 55.5% — sustainability is the question.

LLY generates stronger free cash flow (3.0B), providing more financial flexibility.

Bottom Line

LLY scores higher overall (78/100 vs 13/100), backed by strong 35.0% margins and 55.5% revenue growth. ONMD offers better value entry with a 75.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

OneMedNet Corp.

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

OneMedNet Corporation develops technology that focuses on accessing and sharing health data. The company is headquartered in Eden Prairie, Minnesota with a development office in Vancouver, Canada.

Want to dig deeper into these stocks?